- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01050621
Trial of Chemotherapy Plus Intravenous Vitamin C in Patients With Advanced Cancer for Whom Chemotherapy Alone is Only Marginally Effective
Phase I - II Clinical Trial of Combination Conventional Cytotoxic Chemotherapy and Intravenous Vitamin C in Patients With Advanced Cancer or Hematologic Malignancy for Whom Cytotoxic Chemotherapy Alone is Only Marginally Effective
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cytotoxic chemotherapy is relatively ineffective for a large proportion of common cancers. Combining redox active molecules with certain chemotherapy regimens could increase their anti-cancer activity or protect host tissues from toxicity with no loss of anti-cancer activity. Research in this area has been advocated by cancer organizations, but previous clinical trials of combination chemotherapy and antioxidant therapy been small, poorly designed, and unsystematic. Appropriate study of this treatment concept requires a systematic, meticulous empirical approach similar to the one used in conventional cytotoxic drug discovery. This is a Phase I-II study designed to identify promising chemotherapy-antioxidant protocols and determine their acceptability and limiting toxicity in patients with relentlessly progressive cancers for which conventional chemotherapy is clinically indicated but is known to be minimally or marginally effective.
The tolerable dose of intravenous ascorbic acid (IVAA) for cancer patients with normal renal function not receiving chemotherapy is 1.5 g/kg per 90 to 120 minute infusion (Hoffer et al, Ann Oncol 2008;19:1969-1974). Side effects are minimal to non-existent. In this dose-escalating study the IVAA will be 0.9 g/kg per infusion for the first chemotherapy cycle, increasing to 1.5 g/kg per infusion in subsequent cycles, for the first 3 participants. If well tolerated as expected, the initial dose will be 1.5 g/kg per infusion for subsequent participants. Infusions will take place 2 or 3 times per week, bracketing the days of chemotherapy. Standard tolerance and adverse effect criteria will be used. Therapy will continue for a minimum of 2 months, and continue further in the event of disease stabilization or response, as determined from CT scan and biomarkers, with evaluations continuing every 2 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Clinical Research Unit, Jewish General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- must be a resident of Quebec, Canada
- documented advanced or metastatic cancer or hematologic malignancy in adults over age 18, with measurable disease
- adequate bone marrow, hepatic, renal and cardiac function so as to permit conventional chemotherapy
- no current calcium oxalate nephrolithiasis with the potential to reduce urinary flow
- life expectancy at least 8 weeks.
Exclusion Criteria:
- glucose-6-phosphate dehydrogenase deficiency
- cancers for which existing chemotherapy offers more than a 33% likelihood of a clinically meaningful response
- serum creatinine greater than 175 micromol/L
- serious GI diseases
- infections
- recent major surgery
- dementia
- altered mental status or other condition that would preclude chemotherapy, including poor functional status.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and tolerability of IV ascorbic acid (IVAA) in target dose of 1500 mg/kg supplementing cytotoxic chemotherapeutic drugs. Standard adverse effect criteria will be used.
Time Frame: At every clinic visit
|
At every clinic visit
|
Observe for qualitative indicators that IV ascorbic acid mitigates chemotherapy adverse effects
Time Frame: Every treatment cycle
|
Every treatment cycle
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To monitor for disease arrest or response (RECIST criteria) in a population in which arrest or response is unusual or rare
Time Frame: CT assessment every 2 months
|
CT assessment every 2 months
|
Quality of life assessment using FACT B and POMS R
Time Frame: every month
|
every month
|
Measure the effect of chemotherapy on pharmacokinetics of intravenous ascorbic acid
Time Frame: Before and 5 days following first chemotherapy
|
Before and 5 days following first chemotherapy
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Leonard John Hoffer, MD PhD, Faculty of Medicine, McGill University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VITC-003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on vitamin C (ascorbic acid)
-
In-Young Choi, Ph.D.CompletedType 2 Diabetes | Oxidative StressUnited States
-
DongGuk UniversityKorean Association For Vitamin ResearchCompleted
-
Health Innovations, Frontier Research InstituteTerminatedHepatitis CUnited States
-
Situs Cancer Research CenterSuspendedSarcoma | Adenocarcinoma | Carcinoma | Multiple Myeloma | Desmoplastic Small Round Cell TumorUnited States
-
University of Colorado, DenverNational Institutes of Health (NIH); American Diabetes AssociationCompletedType 2 DiabetesUnited States
-
University of Alabama at BirminghamTerminatedNosocomial Pneumonia | CoagulopathyUnited States
-
Oregon Health and Science UniversityNational Heart, Lung, and Blood Institute (NHLBI); Office of Dietary Supplements...CompletedSecond Hand Smoke | Pulmonary Function; Newborn, Abnormal | Infant Wheeze | In-utero NicotineUnited States
-
Ain Shams UniversityCompleted
-
University of North Carolina, Chapel HillNational Institute of Nursing Research (NINR); Sigma Theta Tau International...Completed
-
University of AberdeenUniversity of OtagoNot yet recruiting